‘Personal Zen’ Mobile App Helps to Ease Anxiety in Pediatric-onset MS
Personal Zen, a digital anxiety management tool developed by Wise Therapeutics, eased anxiety and broad negative moods in…
Articles by Forest Ray PhD
Nurse With MS Wins Grant to Find Severity, Progression Biomarkers
A nurse and PhD candidate with multiple sclerosis (MS) is looking for disease biomarkers that can help healthcare providers…
Botox Approved to Treat Spasticity in 8 New Arm, Hand Muscles
The U.S. Food and Drug Administration (FDA) has expanded the label for Botox (onabotulinumtoxinA) in adults for the treatment…
FDA Greenlights Stem Cells Trial Aiming to Improve Quality of Life
The U.S. Food and Drug Administration (FDA) has given the green light to a Phase 2 clinical trial that will…
At-home Tysabri Infusions Appear as Safe, Effective as Those at Clinics
Tysabri (natalizumab) infusions given in the home to people with relapsing-remitting multiple sclerosis (RRMS) save money and are…
Low Temelimab Doses in RRMS Trial Among Reasons for Poor Results
Low doses selected and underlying inflammatory disease may have confounded the ability of temelimab to significantly affect neuroinflammation in a…
Nerve Tissue Scarring May Explain MS Progression
Nerve tissue scars associated with multiple sclerosis (MS) show marked differences from those of similar neurodegenerative disorders, according to…
Destroying Myelin-damaging Immune Cells May Be New Therapy
Vesicles containing the chemotherapeutic agent doxorubicin can be used to destroy the aberrant, myelin-damaging immune cells that contribute to…
No Negative Effects on Infants Whose Moms Take Copaxone While Breastfeeding
Treatment with Copaxone (glatiramer acetate), an approved therapy for relapsing forms of multiple sclerosis (MS), while breastfeeding does not…
Nasal Foralumab Led to Promising Immune Effects in Phase 1 Trial
Nasally-administered foralumab, a potential treatment for neurodegenerative disorders such as progressive forms of multiple sclerosis (MS), appears safe and…
First SPMS Patient Dosed With Foralumab Nasal Spray
Foralumab, an investigational anti-CD3 antibody that is administered via a nasal spray, has been given for the first time to…
Ponvory Approved in EU for Active Relapsing Forms of MS
The European Commission has approved Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active…
Prize Awarded to Researcher of Microglia’s Role in Brain Diseases
A professor at the University of Freiburg, in Germany, was awarded the Novo Nordisk Prize for his research into the role…
‘Stop Multiple Sclerosis’ Is Theme of World Brain Day
Stop Multiple Sclerosis is the theme of this year’s World Brain Day, taking place July 22 to raise global…
Global Phase 3 Trials of Fenebrutinib Enrolling Relapsing and PPMS Patients
Two global Phase 3 clinical trials comparing fenebrutinib, an investigational oral BTK inhibitor by Roche, with Aubagio…
FDA Rejects Under-the-skin Tysabri for Relapsing MS
The U.S. Food and Drug Administration (FDA) has rejected Biogen‘s request for approval of under-the-skin administration of Tysabri (natalizumab)…
MS Society of Canada Grant to Support AI in Predicting Disease Course
The Multiple Sclerosis Society of Canada has awarded CA$1 million to a project helping doctors who treat multiple sclerosis…
TG Expands Contract With Samsung Biologics to Produce Ublituximab
TG Therapeutics has expanded its contract with Samsung Biologics to manufacture ublituximab, an investigational therapy for relapsing forms…
#AANAM – Vumerity Showing Tolerability, Efficacy in Ongoing EVOLVE-MS-1 Trial
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
#AANAM – Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
#AANAM – Ublituximab Reduced Relapse Rate, Disability Progression in Twin Trials
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
#AANAM – Kesimpta, Added to NHS in UK, Prevents Worsening in New Patients
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
Rates of MS Seem to Rise With Nations’ Prosperity
Rates of multiple sclerosis (MS) appear to rise with measures of prosperity, occurring more frequently in developed countries, according…
Reeve Foundation Launches Support Groups for People Affected by Paralysis
The Christopher & Dana Reeve Foundation has launched virtual support groups for people living with paralysis — either due to…
Wise Will Seek FDA Approval for Digital Anxiety Management Therapy
Wise Therapeutics intends to seek U.S. Food and Drug Administration (FDA) approval of an anxiety management therapy for…
Sanofi Genzyme Launches Recruitment Website for Tolebrutinib Trials
Sanofi Genzyme has launched a website to help connect people with…
Ponvory Recommended for Approval in EU for Relapsing Forms of MS
A branch of the European Medicines Agency has recommended that Ponvory (ponesimod) be approved to treat relapsing forms of…
Health Canada OKs Self-administered Kesimpta for Adults With Active RRMS
Health Canada has approved Kesimpta (ofatumumab) for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) who have active…
Ampyra Aids More Than Walking in MS, But Side Effects May Be of Concern
Treatment with oral Ampyra (dalfampridine) improves walking ability, finger dexterity, and cognition in people with multiple sclerosis (MS), an analysis…
UK Study to Compare Struggles of Patients With ‘Long-COVID-19’ and MS
Researchers in the U.K. are seeking patients who found it difficult to return to work or school after a diagnosis…